BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Catalyst Brief//FDA catalyst calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Catalyst Brief — FDA catalyst calendar
REFRESH-INTERVAL;VALUE=DURATION:PT6H
X-PUBLISHED-TTL:PT6H
BEGIN:VEVENT
UID:event-131@catalystbrief.girapphe.com
DTSTAMP:20261117T181600Z
LAST-MODIFIED:20261117T181600Z
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261202
SUMMARY:Readout: Madrigal Pharmaceuticals\, Inc. — Resmetirom [Dec 2026]
DESCRIPTION:Phase 3 primary completion: A Phase 3 Study to Evaluate the Eff
 ect of Resmetirom on Clinical Outcomes in Patients With Well-compensated N
 ASH Cirrhosis (MAESTRO-NASH-OUTCOMES).\nSource: https://clinicaltrials.gov
 /study/NCT05500222\nhttps://catalystbrief.girapphe.com/e/131?lang=en\nNot 
 investment advice. Dates may change.
URL:https://catalystbrief.girapphe.com/e/131?lang=en
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
